Journey Medical Corporation
Journey Medical Corporation (JMC) is a subsidiary of Fortress Biotech, Inc. formed in October 2014. JMC is an innovative company focused on developing, acquiring, licensing, and commercializing branded dermatology products. Journey has launched four products in the past year; three of those products are under the Journey name and one is a co-promote agreement.
Most recently Journey launched TargadoxTM, a 50 mg immediate-release doxycycline hyclate coated tablet. Targadox is indicated as adjunctive therapy for severe acne. In 2016, Journey has also launched Luxamend® Wound Cream and CeracadeTM Skin Emulsion. Journey also has an agreement to co-promote Dermasorb HC for Crown Labs.
JMC is headquartered in Scottsdale, Arizona and is led by President and CEO, Claude Maraoui, who has more than 25 years of experience in commercializing dermatology products.
Fortress Biotech currently owns >50% of Journey Medical Corporation.
For more information, please visit: www.jmcderm.com